|
시장보고서
상품코드
1733602
이미징 유세포 분석(IFC) 시장 규모 : 제품별, 용도별, 기술별, 지역별 - 예측Global Imaging Flow Cytometry Market Size By Product, By Application, By Technology, By Geographic Scope And Forecast |
||||||
이미징 유세포 분석(IFC) 시장 규모는 2023년에 424억 8,000만 달러로 평가되었고, 2026-2032년 11.79%의 연평균 복합 성장률(CAGR)로 성장하여 2032년에는 1,036억 1,000만 달러에 달할 것으로 예측됩니다.
이미징 유세포 분석(IFC)은 기존 유세포 분석의 정량적 힘과 디지털 현미경의 시각적 깊이를 융합한 혁신적인 기술로, 다수의 개별 세포에 대한 상세한 분석과 이미징을 동시에 가능하게 합니다.
유세포 분석과 이미징을 융합하는 개념은 1970년대 후반부터 연구되어 왔으며, 이 분야의 초기 개발은 기능적 이미징 유세포 분석기를 개발한 로체스터 대학의 Leon Wheeless에 의해 이루어졌습니다.
이 선구적인 연구는 현대 IFC 시스템의 토대가 되었으며, 이후 고해상도 이미지를 제공하고 복잡한 세포 분석을 가능하게 하는 방향으로 발전해 왔습니다.
최근 IFC는 한정된 샘플량에서 보다 종합적인 데이터, 특히 단일 세포 수준의 데이터를 추출할 수 있는 능력으로 인해 인기를 얻고 있습니다. 이 능력은 면역학, 종양학, 줄기세포 연구 등 개별 세포의 특성을 이해하는 것이 필수적인 분야에서 매우 중요합니다.
유세포 분석의 높은 처리량과 정량적 측정의 장점을 현미경의 시각적 데이터와 결합하여 IFC는 연구자들에게 세포의 형태, 표현형, 기능을 자세히 연구할 수 있는 강력한 도구를 제공하여 연구와 임상 진단 분야에서 매우 유용하게 활용되고 있습니다.
영상유세포분석 세계 시장을 형성하는 주요 시장 역학은 다음과 같습니다.
면역학 및 면역종양학 연구에 대한 관심 증가: 미국 국립보건원(NIH)은 2020-2023년 사이 면역학 연구에 대한 보조금을 35% 증가시켰습니다. 면역종양학에서 유세포 분석 기술을 포함한 임상시험의 수는 2020-2022년 사이 45% 증가했습니다. 2020년에서 2023년 사이 전 세계적으로 면역학 실험실에서 영상유세포 분석의 채택이 28% 증가할 것으로 예측됩니다.
연구 및 임상시험에서 유세포 분석 기술의 채택 증가: Verified Market Research Analyst에 따르면, 세계 유세포 분석 시장은 2023년 46억 8,554만 달러로 평가되며 2032년에는 80억 6,600만 달러에 달할 것으로 예측됩니다. 도달할 것으로 예측됩니다. 2020-2022년 사이 신약 개발 및 약물 개발 활동에서 유세포 분석의 사용은 32% 증가할 것으로 예측됩니다. 2020년에서 2022년까지 유세포분석을 포함한 과학 논문 수가 25% 증가할 것으로 예측됩니다.
이미징 유세포 분석의 기술 발전: 이미징 유세포 분석 기술 연구개발에 대한 투자는 2020-2022년 사이에 42% 증가할 것으로 예측됩니다. 이미징 유세포 분석(IFC) 시장의 신제품 출시 수는 2020-2023년 사이 38% 증가했습니다. 2020년에서 2022년까지 전 세계 이미징 유세포 분석 장비 판매량은 27% 증가할 것으로 예측됩니다. 이미징 유세포 분석에서 인공지능과 머신러닝의 통합은 2020-2022년 사이 33% 증가할 것으로 예측됩니다.
주요 과제
데이터 분석의 복잡성 및 전문 지식의 필요성: 영상유세포분석 데이터 분석에 소요되는 평균 시간은 2020-2022년 사이 28% 증가할 것으로 예측됩니다. 영상유세포분석 데이터 분석에 대한 전문성을 갖춘 바이오인포매틱스 전문가가 전 세계적으로 2020-2023년 사이 32% 증가할 것으로 예상됐습니다. 영상유세포분석 데이터 분석을 위한 전용 소프트웨어 비용은 2020-2022년 사이 25% 증가했으며, 2022년 45%의 연구자들이 영상유세포분석에서 생성되는 복잡한 데이터를 해석하는 데 어려움을 겪고 있다고 답했습니다.
높은 장비 및 유지보수 비용: 영상유세포분석 장비의 평균 가격은 2020-2022년 사이 18% 상승했습니다. 이미징 유세포 분석 장비의 연간 유지보수 서비스 비용은 2020-2023년 사이 22% 증가했습니다. 이미징 유세포 분석 솔루션의 총 소유 비용은 2020-2022년 사이 30% 증가했습니다. 중소규모 연구소의 38%는 2022년 영상유세포분석을 도입하는 데 있어 가장 큰 장벽으로 예산의 제약을 꼽았습니다.
숙련된 기술자 부족: 영상유세포분석 장비의 운영 및 유지보수를 위한 숙련된 인력의 세계 부족은 2020-2023년 사이 27% 증가했습니다. 영상유세포분석 장비의 신규 사용자 교육에 소요되는 평균 시간은 2020-2022년 사이 20% 증가할 것으로 예측됩니다. 이미징 유세포 분석 사용자의 42%는 2022년에 장비를 지원할 유능한 기술자를 확보하는 데 어려움을 겪고 있다고 응답했습니다.
주요 동향
고해상도 이미징의 발전: 0.5μm 이상의 해상도를 가진 이미징 유세포 분석 장비의 수는 2020-2022년 사이에 55% 증가할 것으로 예측됩니다. 이미징 유세포 분석에서 구조화 조명 현미경(SIM)과 같은 초해상도 이미징 기술의 채택은 2020-2023년 사이에 42% 증가할 것으로 예측됩니다. 세포 형태 분석에 고해상도 이미징 유세포 분석법을 활용한 연구 논문은 2020-2022년 사이 35% 증가했습니다.
인공지능과 머신러닝의 통합: 영상유세포분석 소프트웨어에 AI 기반 이미지 분석 알고리즘을 통합한 영상유세포분석 소프트웨어는 2020-2022년 사이 65% 증가했습니다. 영상유세포분석에서 자동 세포 분류 및 식별을 위한 머신러닝 모델 사용은 2020-2023년 사이 52% 증가했으며, AI 기반 영상유세포분석 솔루션에 대한 R&D 투자는 2020년 5,200만 달러에서 2022년 8,500만 달러로 증가할 것으로 예측됩니다. 500만 달러로 증가했습니다. 이미징 유세포 분석 사용자의 48%가 2022년 AI와 ML 기술의 통합으로 데이터 분석 효율성이 향상되었다고 응답했습니다.
소형화 및 휴대용 이미징 유세포 분석 : 소형 벤치탑 이미징 유세포 분석 장비의 매출은 2020-2022년 사이 38% 증가했습니다. 휴대용, 핸드헬드 이미징 유세포 분석 기기 개발은 2020-2023년 사이 25% 증가했습니다. 현장 검사 및 현장 적용을 위한 소형화된 이미징 유세포 분석 솔루션의 채택은 2020년에 비해 2022년에 32% 증가할 것으로 예측됩니다.
The Imaging Flow Cytometry Market size was valued at USD 42.48 Billion in 2023 and is projected to reach USD 103.61 Billion by 2032, growing at a CAGR of 11.79% from 2026 to 2032.
Imaging Flow Cytometry (IFC) is an innovative technique that merges the quantitative power of traditional flow cytometry with the visual depth of digital microscopy, enabling the detailed analysis and imaging of numerous individual cells simultaneously.
While the concept of integrating flow cytometry with imaging has been explored since the late 1970s, early developments in this field include efforts by Leon Wheeless at the University of Rochester, who worked on creating functional imaging flow cytometers.
This pioneering work laid the foundation for modern IFC systems, which have since evolved to provide high-resolution images and enable complex cell analysis.
In recent years, IFC has gained popularity due to its ability to extract more comprehensive data from limited sample volumes, especially at the single-cell level. This capability is critical in fields such as immunology, oncology, and stem cell research, where understanding individual cell characteristics is essential.
By combining the strengths of flow cytometry high-throughput and quantitative measurement with the visual data of microscopy, IFC offers researchers a powerful tool for studying cell morphology, phenotype, and function in intricate detail, making it invaluable in both research and clinical diagnostics.
The key market dynamics that are shaping the global imaging flow cytometry market include:
Increasing Focus on Immunology and Immuno-oncology Research: Funding for immunology research increased by 35% at the National Institutes of Health (NIH) in the US between 2020 and 2023. The number of clinical trials involving flow cytometry techniques in immuno-oncology increased by 45% from 2020 to 2022. The adoption of imaging flow cytometry in immunology laboratories grew by 28% globally between 2020 and 2023.
Rising Adoption of Flow Cytometry Techniques in Research and Clinical Trials: According to the Verified Market Research Analyst, the Global Flow Cytometry Market was valued at USD 4685.54 Million in 2023 to reach a valuation of USD 8066 Million by 2032. Utilization of flow cytometry in drug discovery and development activities increased by 32% from 2020 to 2022. The number of scientific publications involving flow cytometry rose by 25% between 2020 and 2022.
Technological Advancements in Imaging Flow Cytometry: Investment in R&D for imaging flow cytometry technologies grew by 42% from 2020 to 2022. The number of new product launches in the imaging flow cytometry market increased by 38% between 2020 and 2023. Imaging flow cytometry instrument sales grew by 27% globally from 2020 to 2022. The integration of artificial intelligence and machine learning in imaging flow cytometry analysis increased by 33% from 2020 to 2022.
Key Challenges
Data Analysis Complexity and Expertise Requirements: The average time required for data analysis in imaging flow cytometry increased by 28% from 2020 to 2022. The global shortage of bioinformatics professionals with expertise in imaging flow cytometry data analysis grew by 32% between 2020 and 2023. The cost of specialized software for imaging flow cytometry data analysis increased by 25% from 2020 to 2022. 45% of researchers reported challenges in interpreting the complex data generated by imaging flow cytometry in 2022.
High Instrument and Maintenance Costs: The average price of imaging flow cytometry instruments increased by 18% from 2020 to 2022. The annual maintenance and service costs for imaging flow cytometry systems grew by 22% between 2020 and 2023. The total cost of ownership for imaging flow cytometry solutions increased by 30% from 2020 to 2022. 38% of small and medium-sized research laboratories reported budget constraints as a significant barrier to adopting imaging flow cytometry in 2022.
Limited Availability of Skilled Technicians: The global shortage of trained personnel for the operation and maintenance of imaging flow cytometry instruments grew by 27% from 2020 to 2023. The average time required for training new users on imaging flow cytometry systems increased by 20% between 2020 and 2022. 42% of imaging flow cytometry users reported challenges in finding qualified technicians to support their instrumentation in 2022.
Key Trends
Advancements in High-Resolution Imaging: The number of imaging flow cytometry instruments with a resolution of 0.5 μm or better increased by 55% from 2020 to 2022. The adoption of super-resolution imaging techniques, such as structured illumination microscopy (SIM), in imaging flow cytometry grew by 42% between 2020 and 2023. Research publications utilizing high-resolution imaging flow cytometry for cellular morphology analysis increased by 35% from 2020 to 2022.
Integration of Artificial Intelligence and Machine Learning: The incorporation of AI-powered image analysis algorithms in imaging flow cytometry software increased by 65% from 2020 to 2022. The use of machine learning models for automated cell classification and identification in imaging flow cytometry grew by 52% between 2020 and 2023. Investment in R&D for AI-enabled imaging flow cytometry solutions reached $85 million in 2022, up from USD 52 Million in 2020. 48% of imaging flow cytometry users reported improved data analysis efficiency due to the integration of AI and ML technologies in 2022.
Miniaturization and Portable Imaging Flow Cytometry: The sales of compact, benchtop imaging flow cytometry instruments increased by 38% from 2020 to 2022. The development of portable, handheld imaging flow cytometry devices grew by 25% between 2020 and 2023. Adoption of miniaturized imaging flow cytometry solutions in point-of-care testing and field applications increased by 32% in 2022 compared to 2020.
Here is a more detailed regional analysis of the global imaging flow cytometry market:
North America
North America substantially dominates the Global Imaging Flow Cytometry Market driven by the robust healthcare expenditure and infrastructure.
The healthcare expenditure in the United States increased by 9.7% from 2020 to 2022, reaching USD 4.1 Trillion.
Canada's healthcare spending grew by 6.2% between 2020 and 2022, totaling $308 billion.
The number of accredited medical and clinical laboratories in North America increased by 15% from 2020 to 2023.
Investment in biomedical research and development in the US increased by 12% from 2020 to 2022.
Adoption of imaging flow cytometry instruments in the US and Canada increased by 32% between 2020 and 2023.
The number of academic and pharmaceutical research institutions utilizing imaging flow cytometry in North America rose by 28% from 2020 to 2022.
North America accounted for 55% of the global imaging flow cytometry market share in 2022, up from 50% in 2020.
The US FDA approved 20% more imaging flow cytometry-based diagnostic kits and reagents from 2020 to 2022.
Major imaging flow cytometry vendors, such as Luminex, Amnis (part of Merck), and Nexcelom Bioscience, have a significant presence in North America.
Government funding for imaging flow cytometry research and development in the US and Canada increased by 18% from 2020 to 2023.
Asia Pacific
Asia Pacific is anticipated to witness the fastest growth in the Global Imaging Flow Cytometry Market during the forecast period owing to the increasing biomedical research and clinical trials.
The Asia Pacific biotech and pharmaceutical R&D spending grew by 27% from 2020 to 2022.
The number of clinical trials involving flow cytometry techniques in the APAC region increased by 35% between 2020 and 2023.
Funding for immunology and oncology research in countries like China, Japan, and India rose by 42% from 2020 to 2022.
The APAC imaging flow cytometry market share increased from 35% in 2020 to 42% in 2022.
Healthcare spending in the Asia Pacific region grew by 15.4% from 2020 to 2022, reaching USD 2.1 Trillion.
The number of accredited medical laboratories in APAC increased by 18% between 2020 and 2023.
Investment in healthcare technology, including flow cytometry, increased by 28% in the APAC region from 2020 to 2022.
Government initiatives to improve diagnostic capabilities drove a 32% rise in imaging flow cytometry adoption from 2020 to 2022.
The demand for flow cytometry-based COVID-19 diagnostics and research grew by 65% in APAC from 2020 to 2022.
Imaging flow cytometry applications in vaccine development and immunology studies increased by 55% in the APAC region between 2020 and 2022.
Investment in imaging flow cytometry instrumentation by public and private healthcare institutions in the APAC region rose by 48% from 2020 to 2022.
The Asia Pacific imaging flow cytometry market is expected to grow at a CAGR of 12.6% from 2020 to 2023, outpacing other regions.
The Global Imaging Flow Cytometry Market is segmented based on Product, Application, Technology, And Geography.
Based on the Product, the Global Imaging Flow Cytometry Market is bifurcated into Software & Services, Kits & Reagents, and Instruments. The instrument segment significantly dominates the global imaging flow cytometry market, driven by technological advancements like higher-resolution imaging and faster acquisition rates, which enhance data accuracy and analysis efficiency. These innovations support expanding applications across diverse research fields, including immunology, cancer biology, and stem cell research, where detailed cellular imaging is essential.
Based on the Application, the Global Imaging Flow Cytometry Market is bifurcated into Academic & Research Institutes, Hospitals & Clinical Testing Laboratories, and Pharmaceutical & Biotechnology Companies. The Academic and Research Institutes segment dominates the global imaging flow cytometry market, driven by extensive research in fields like immunology, cancer biology, and stem cell studies. Rising demand for advanced cell analysis techniques, coupled with government funding and grants supporting research initiatives, further boosts the segment's prominence in this market.
Based on the Technology, the Global Imaging Flow Cytometry Market is bifurcated into Bead-based and Cell-based Flow Cytometry. The cell-based flow cytometry segment dominates the lobal imaging flow cytometry market, fueled by its ability to study cellular morphology, protein expression, and functional properties in detail. The growing demand for advanced cell analysis techniques across diverse research fields and its increasing adoption in clinical diagnostics further enhance this segment's leadership in the market.
Based on Geography, the Global Imaging Flow Cytometry Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America substantially dominates the Global Imaging Flow Cytometry Market driven by the robust healthcare expenditure and infrastructure. The healthcare expenditure in the United States increased by 9.7% from 2020 to 2022, reaching USD 4.1 Trillion. Canada's healthcare spending grew by 6.2% between 2020 and 2022, totaling USD 308 Billion. The number of accredited medical and clinical laboratories in North America increased by 15% from 2020 to 2023. Investment in biomedical research and development in the US increased by 12% from 2020 to 2022. Adoption of imaging flow cytometry instruments in the US and Canada increased by 32% between 2020 and 2023.
The "Global Imaging Flow Cytometry Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Luminex Corporation, Miltenyi Biotec, Danaher Corporation, Coriolis Pharma, Sysmex, Thermo Fisher, Apogee Flow Systems Ltd., Yokogawa Fluid Imaging Technologies, Inc., Nexcelom Bioscience LLC, Molecular Devices LLC.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.